MedTrace Logo

Short-term Intravenous Iron Isomaltose Anhydride for IDA

NCT03915327 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2024-05-06

No results posted yet for this study

Summary

This prospective, randomized, controlled study aims to evaluate the impact of short-term intravenous iron isomaltose anhydride on postoperative recovery and the requirement for allogeneic red blood cells (RBC) transfusion in preoperative Iron-deficiency anemia (IDA) patients receiving orthopedic surgery, thus facilitating developing a simple and effective iron supplement approach for patients' recovery.

Conditions

Interventions

DRUG

Intravenous iron isomaltose anhydride

Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Ren Liao, M.D. · Department of Anesthesiology, West China Hospital, Sichuan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-05
Primary Completion
2028-05-31
Completion
2029-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03915327 on ClinicalTrials.gov